NCT05046132View on ClinicalTrials.gov

Study of Setmelanotide Effects on QTc (Corrected QT) Interval in Healthy Participants

PHASE4CompletedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

August 5, 2021

Primary Completion Date

April 7, 2022

Study Completion Date

April 7, 2022

Conditions
Healthy
Interventions
DRUG

Setmelanotide

Administered once daily via SC injection.

DRUG

Moxifloxacin

Moxifloxacin capsules via oral administration.

DRUG

Oral Placebo

Placebo capsules via oral administration.

DRUG

SC Placebo

Placebo via SC injection.

Trial Locations (1)

91206

Parexel Early Phase Clinical Unit (Los Angeles), Glendale

All Listed Sponsors
lead

Rhythm Pharmaceuticals, Inc.

INDUSTRY

NCT05046132 - Study of Setmelanotide Effects on QTc (Corrected QT) Interval in Healthy Participants | Biotech Hunter | Biotech Hunter